P120: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A CROSSWALK-C TRIAL EVALUATING THE EFFICACY OF CROVALIMAB AS ADJUNCT TREATMENT IN THE PREVENTION OF VASO-OCCLUSIVE EPISODES (VOES) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD)

• M Callaghan,
• K Ataga,
• L De Franceschi,
• C Minniti,
• N Balachandran,
• D Imbs,
• T Perretti,
• J Ramos,
• A Sostelly,
• P Bartolucci

Affiliations

M Callaghan

1 Division of Pediatric Hematology/Oncology, Central Michigan University SOM, Children’s Hospital of Michigan, Detroit, MI, UNITED STATES

K Ataga

2 UTHSC Center for Sickle Cell Disease, Memphis, TN, UNITED STATES

L De Franceschi

3 Department of Medicine, University of Verona and AOUI Verona, Verona, ITALY

C Minniti

4 Albert Einstein College of Medicine, Bronx, New York, NY, UNITED STATES

N Balachandran

5 Roche Products Limited, Welwyn Garden City, UNITED KINGDOM

D Imbs

6 Certara, Inc., Paris, FRANCE

T Perretti

7 F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND

J Ramos

8 Genentech Inc., South San Francisco, CA, UNITED STATES

A Sostelly

7 F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND

P Bartolucci

9 University Paris-East Créteil, Sickle Cell Referral Center - UMGGR & IMRB, Laboratory of Excellence LABEX GRex, Créteil, FRANCE